Orexo AB (ORX) - Total Liabilities
Based on the latest financial reports, Orexo AB (ORX) has total liabilities worth Skr245.70 Million SEK (≈ $26.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Orexo AB - Total Liabilities Trend (2002–2025)
This chart illustrates how Orexo AB's total liabilities have evolved over time, based on quarterly financial data. See Orexo AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Orexo AB Competitors by Total Liabilities
The table below lists competitors of Orexo AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Biodesix Inc
NASDAQ:BDSX
|
USA | $90.44 Million |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
Spain | €78.33 Million |
|
Definitive Healthcare Corp
NASDAQ:DH
|
USA | $356.50 Million |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $123.36 Million |
|
Drilling Tools International Corp.
NASDAQ:DTI
|
USA | $104.27 Million |
|
Vera Bradley Inc
NASDAQ:VRA
|
USA | $115.62 Million |
|
VIVANI MED.INC. NEW O.N.
F:U5P
|
Germany | €23.66 Million |
|
The Sandesh Limited
NSE:SANDESH
|
India | Rs991.87 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Orexo AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Orexo AB market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orexo AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orexo AB (2002–2025)
The table below shows the annual total liabilities of Orexo AB from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr812.20 Million ≈ $87.41 Million |
+12.63% |
| 2024-12-31 | Skr721.10 Million ≈ $77.60 Million |
-0.91% |
| 2023-12-31 | Skr727.70 Million ≈ $78.31 Million |
-20.48% |
| 2022-12-31 | Skr915.10 Million ≈ $98.48 Million |
-0.97% |
| 2021-12-31 | Skr924.10 Million ≈ $99.45 Million |
+37.03% |
| 2020-12-31 | Skr674.40 Million ≈ $72.58 Million |
-15.14% |
| 2019-12-31 | Skr794.70 Million ≈ $85.52 Million |
-1.96% |
| 2018-12-31 | Skr810.60 Million ≈ $87.23 Million |
+20.12% |
| 2017-12-31 | Skr674.80 Million ≈ $72.62 Million |
-4.76% |
| 2016-12-31 | Skr708.50 Million ≈ $76.25 Million |
-5.51% |
| 2015-12-31 | Skr749.85 Million ≈ $80.70 Million |
-2.73% |
| 2014-12-31 | Skr770.86 Million ≈ $82.96 Million |
+26.19% |
| 2013-12-31 | Skr610.87 Million ≈ $65.74 Million |
+110.24% |
| 2012-12-31 | Skr290.56 Million ≈ $31.27 Million |
+23.64% |
| 2011-12-31 | Skr235.00 Million ≈ $25.29 Million |
-3.87% |
| 2010-12-31 | Skr244.45 Million ≈ $26.31 Million |
+142.82% |
| 2009-12-31 | Skr100.67 Million ≈ $10.83 Million |
-23.87% |
| 2008-12-31 | Skr132.24 Million ≈ $14.23 Million |
+1.24% |
| 2007-12-31 | Skr130.62 Million ≈ $14.06 Million |
+135.01% |
| 2006-12-31 | Skr55.58 Million ≈ $5.98 Million |
+71.54% |
| 2005-12-31 | Skr32.40 Million ≈ $3.49 Million |
+21.90% |
| 2004-12-31 | Skr26.58 Million ≈ $2.86 Million |
+186.74% |
| 2003-12-31 | Skr9.27 Million ≈ $997.60K |
+19.91% |
| 2002-12-31 | Skr7.73 Million ≈ $831.98K |
-- |
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more